Skip to main content

Australia’s active vaccine safety system

Secondary Menu

  • Contact
  • About us
  • Vaccine safety surveillance
    • How vaccine safety surveillance works
    • How AusVaxSafety works
    • Information for immunisation providers
    • Information for immunisation recipients
    • Publications
  • Vaccine safety data
    • COVID-19 vaccines
    • Influenza vaccines
    • Mpox (monkeypox) vaccine
    • National Immunisation Program schedule vaccines
    • Nirsevimab
    • RSV vaccines
    • Vaccine safety in Australia AusVaxSafety summary reports
  • News & events
  • Resources
  • Contact

Main navigation

  • About us
  • Vaccine safety surveillance
    • How vaccine safety surveillance works
    • How AusVaxSafety works
    • Information for immunisation providers
    • Information for immunisation recipients
    • Publications
  • Vaccine safety data
    • COVID-19 vaccines
    • Influenza vaccines
    • Mpox (monkeypox) vaccine
    • National Immunisation Program schedule vaccines
    • Nirsevimab
    • RSV vaccines
    • Vaccine safety in Australia AusVaxSafety summary reports
  • News & events
  • Resources
News & events
14 July 2025 | News
Fewer adverse events reported following NIP pneumococcal vaccine change
03 June 2025 | News
New AusVaxSafety data confirms Abrysvo RSV vaccine is well tolerated during pregnancy; adverse events comparable to other maternal vaccinations
18 May 2025 | News
2025 Australian flu season: Who should get a flu shot, which vaccines are available and what to expect in the days following your vaccination
31 March 2025 | News
AusVaxSafety commences routine surveillance of 2025 seasonal influenza vaccines
10 March 2025 | News
New JN.1 COVID-19 vaccines well tolerated, AusVaxSafety data show
06 March 2025 | News
AusVaxSafety publishes Australian-first safety data for Arexvy RSV vaccine
08 January 2025 | News
New report re-affirms short-term safety of vaccines in Australia
08 November 2024 | News
Enhanced National Immunisation Program vaccine safety data now available
23 October 2024 | News
AusVaxSafety study affirms short-term safety profile of Moderna and Novavax COVID-19 vaccine priming doses
01 October 2024 | News
AusVaxSafety marks a decade of progress in vaccine safety
All news & events
Tue, 01/17/2017 | News

The backstory to a landmark development for vaccine safety

 Access the full Croakey article here.

Share this article:

Navigate

  • Contact Us
  • Disclaimer
  • Privacy
  • Accessibility

AusVaxSafety receives funding
from the Australian Government

NCIRS, Kids Research, Sydney Children’s Hospitals Network, Cnr Hawkesbury Rd & Hainsworth St, Westmead Locked Bag 4001, Westmead NSW 2145 Tel (612) 9845 1433  |  Fax (612) 9845 1418  |  ABN 53 188 579 090

We acknowledge that the National Centre for Immunisation Research and Surveillance (NCIRS) is on the land of the traditional owners the Aboriginal and Torres Strait Islander peoples, the First Australians, and recognise their culture, history, diversity and their deep connection to the land. Together, through research and partnership, we aim to move to a place of equity for all. NCIRS also acknowledges and pays respect to other Aboriginal and Torres Strait Islander nations from which our research, staff and community are drawn.

Copyright © 2025 AusVaxSafety. All rights reserved

vaccine

Our website meets the criteria for credibility and content as defined by the Global Advisory Committee on Vaccine Safety.

Subscribe to our newsletter for immunisation professionals

Stay updated with the latest from NCIRS

 
  • Contact Us
  • Disclaimer
  • Privacy
  • Accessibility
Subscribe to our newsletter for immunisation professionals

Stay updated with the latest from ausvax

 

NCIRS, Kids Research, Sydney Children’s Hospitals Network, Cnr Hawkesbury Rd & Hainsworth St, Westmead Locked Bag 4001, Westmead NSW 2145 Tel (612) 9845 1433  |  Fax (612) 9845 1418  |  ABN 53 188 579 090

Our website meets the criteria for credibility and content as defined by the Global Advisory Committee on Vaccine Safety.

We acknowledge that the National Centre for Immunisation Research & Surveillance (NCIRS) is on the land of the traditional owners the Aboriginal and Torres Strait Islander peoples, the First Australians, and recognise their culture, history, diversity and their deep connection to the land. Together, through research and partnership, we aim to move to a place of equity for all. NCIRS also acknowledges and pays respect to other Aboriginal and Torres Strait Islander nations from which our research, staff and community are drawn.